As of 11:58am ET
| +0.135 / +0.31%|
The 16 analysts offering 12-month price forecasts for Novozymes A/S have a median target of 39.69, with a high estimate of 49.77 and a low estimate of 32.16. The median estimate represents a -10.17% decrease from the last price of 44.19.
The current consensus among 19 polled investment analysts is to Sell stock in Novozymes A/S. This rating has held steady since June, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.